ANTHONY R. MATO
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
- Where
- ITHACA, NY
- NPI
- 1053473983
- Received
- $920,319 in 248 records, 2019 to 2025 ($909,245 general, $11,074 research)
- As principal investigator
- $39,396,739 of research payments to others in 398 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 11 | $310,487 |
| 2024 | General payment | 21 | $228,014 |
| 2023 | General payment | 18 | $154,970 |
| 2022 | General payment | 45 | $38,296 |
| 2021 | General payment | 45 | $59,334 |
| 2021 | Research payment | 2 | $4,991 |
| 2020 | General payment | 22 | $42,038 |
| 2020 | Research payment | 3 | $1,901 |
| 2019 | General payment | 74 | $76,103 |
| 2019 | Research payment | 7 | $4,182 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 110 | $854,016 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 9 | $27,042 |
| Travel and Lodging | 23 | $18,120 |
| Research payment | 12 | $11,074 |
| Food and Beverage | 88 | $6,247 |
| Honoraria | 2 | $3,760 |
| Education | 4 | $58 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | AstraZeneca Pharmaceuticals LP | $94,240 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-30 | AstraZeneca Pharmaceuticals LP | $77,794 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-07 | AstraZeneca Pharmaceuticals LP | $71 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-17 | Adaptive Biotechnologies Corporation | $800 | Consulting Fee | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-07-17 | Adaptive Biotechnologies Corporation | $800 | Consulting Fee | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-06-30 | AstraZeneca Pharmaceuticals LP | $77,794 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-25 | Adaptive Biotechnologies Corporation | $3,600 | Consulting Fee | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-05-07 | Novartis Pharmaceuticals Corporation | $69 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-03-31 | AstraZeneca Pharmaceuticals LP | $53,501 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-03-06 | Adaptive Biotechnologies Corporation | $1,800 | Consulting Fee | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-02-21 | Adaptive Biotechnologies Corporation | $16 | Food and Beverage | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $17,233 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-14 | Amgen Inc. | $29 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-11 | Tempus AI, Inc | $1,750 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-22 | Tempus AI, Inc | $500 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-10 | Adaptive Biotechnologies Corporation | $5,200 | Consulting Fee | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | 2024 | |
| 2024-09-30 | AstraZeneca Pharmaceuticals LP | $58,484 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-09-04 | Tempus AI, Inc | $2,125 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-09-04 | Tempus AI, Inc | $500 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-08-05 | Tempus AI, Inc | $2,000 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-30 | AstraZeneca Pharmaceuticals LP | $59,581 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-12 | Tempus AI, Inc | $3,750 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-12 | Tempus AI, Inc | $1,250 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-05-24 | Adaptive Biotechnologies Corporation | $6,800 | Consulting Fee | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | 2024 | |
| 2024-05-24 | Adaptive Biotechnologies Corporation | $1,400 | Consulting Fee | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | 2024 | |
| 2024-05-24 | Adaptive Biotechnologies Corporation | $301 | Travel and Lodging | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | 2024 | |
| 2024-05-24 | Adaptive Biotechnologies Corporation | $182 | Travel and Lodging | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | 2024 | |
| 2024-05-24 | Novartis Pharmaceuticals Corporation | $96 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-03-31 | AstraZeneca Pharmaceuticals LP | $65,604 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-02-29 | ABBVIE INC. | $97 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2024 | |
| 2024-02-07 | Tempus AI, Inc | $100 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-01-26 | AstraZeneca Pharmaceuticals LP | $1,027 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2024 | |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $81,339 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-09 | Genmab U.S., Inc. | $136 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2023 | |
| 2023-09-30 | AstraZeneca Pharmaceuticals LP | $39,474 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-24 | Adaptive Biotechnologies Corporation | $4,400 | Consulting Fee | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | 2023 | |
| 2023-08-14 | Pharmacyclics LLC, an AbbVie Company | $19 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2023 | |
| 2023-08-10 | Adaptive Biotechnologies Corporation | $4,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | 2023 | |
| 2023-08-10 | Adaptive Biotechnologies Corporation | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | 2023 | |
| 2023-07-27 | ABBVIE INC. | $1,375 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2023 | |
| 2023-07-19 | AstraZeneca Pharmaceuticals LP | $2,055 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2023 | |
| 2023-07-19 | Adaptive Biotechnologies Corporation | $112 | Food and Beverage | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | 2023 | |
| 2023-07-13 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | Columvi Biological, BioOncology | 2023 | |
| 2023-06-30 | AstraZeneca Pharmaceuticals LP | $14,700 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-05-04 | Adaptive Biotechnologies Corporation | $97 | Food and Beverage | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | 2023 | |
| 2023-05-02 | ABBVIE INC. | $1,100 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2023 | |
| 2023-04-28 | SERVIER PHARMACEUTICALS LLC | $18 | Food and Beverage | In-kind items and services | Tibsovo Drug, Oncology | 2023 | |
| 2023-01-26 | Boston Scientific Corporation | $142 | Food and Beverage | In-kind items and services | Device, General - IO Ablation_PI | 2023 | |
| 2023-01-18 | Pharmacyclics LLC, an AbbVie Company | $550 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | 2023 | |
| 2023-01-16 | AstraZeneca Pharmaceuticals LP | $3,425 | Consulting Fee | Cash or cash equivalent | LUMOXITI Biological, Oncology | 2023 | |
| 2022-12-21 | AstraZeneca Pharmaceuticals LP | $1,712 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2022 | |
| 2022-12-12 | Genentech, Inc. | $660 | Consulting Fee | Cash or cash equivalent | Drug | 2022 | |
| 2022-12-12 | Eli Lilly and Company | $659 | Travel and Lodging | In-kind items and services | 2022 | ||
| 2022-12-12 | SEAGEN INC. | $42 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-12-09 | AstraZeneca Pharmaceuticals LP | $135 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2022 | |
| 2022-12-09 | AstraZeneca Pharmaceuticals LP | $55 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2022 | |
| 2022-12-08 | ABBVIE INC. | $111 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2022 | |
| 2022-12-08 | Eli Lilly and Company | $103 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-12-08 | AstraZeneca Pharmaceuticals LP | $42 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2022 | |
| 2022-10-25 | AstraZeneca Pharmaceuticals LP | $266 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-10-10 | Pharmacyclics LLC, an AbbVie Company | $550 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | 2022 | |
| 2022-10-07 | ABBVIE INC. | $1,375 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2022 | |
| 2022-09-29 | SEAGEN INC. | $146 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-09-19 | E.R. Squibb & Sons, L.L.C. | $2,768 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-09-01 | Pharmacyclics LLC, an AbbVie Company | $550 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | 2022 | |
| 2022-08-25 | Genentech, Inc. | $660 | Consulting Fee | Cash or cash equivalent | Drug | 2022 | |
| 2022-07-21 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2022 | |
| 2022-07-20 | E.R. Squibb & Sons, L.L.C. | $1,384 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-19 | Eli Lilly and Company | $43 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-07-18 | SEAGEN INC. | $72 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-07-11 | Janssen Global Services, LLC | $1,550 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, Oncology | 2022 | |
| 2022-07-01 | BeiGene USA, Inc. | $3,250 | Consulting Fee | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2022 | |
| 2022-06-27 | Janssen Biotech, Inc. | $1,550 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, Oncology | 2022 | |
| 2022-06-12 | SEAGEN INC. | $37 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-06-11 | Pharmacyclics LLC, an AbbVie Company | $35 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2022 | |
| 2022-06-10 | Genentech, Inc. | $91 | Food and Beverage | In-kind items and services | Drug | 2022 | |
| 2022-06-08 | ABBVIE INC. | $77 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2022 | |
| 2022-06-08 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2022 | |
| 2022-06-07 | Eli Lilly and Company | $35 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-06-04 | Eli Lilly and Company | $117 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-06-04 | Pharmacyclics LLC, an AbbVie Company | $105 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2022 | |
| 2022-06-04 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2022 | |
| 2022-06-02 | ABBVIE INC. | $105 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2022 | |
| 2022-05-23 | Janssen Biotech, Inc. | $24 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, Oncology | 2022 | |
| 2022-04-01 | Lilly USA, LLC | $2,400 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-03-28 | Genentech, Inc. | $3,300 | Consulting Fee | Cash or cash equivalent | Drug | 2022 | |
| 2022-03-24 | BeiGene USA, Inc. | $1,950 | Consulting Fee | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2022 | |
| 2022-03-11 | AstraZeneca Pharmaceuticals LP | $125 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-03-10 | E.R. Squibb & Sons, L.L.C. | $1,384 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-02-26 | ABBVIE INC. | $95 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2022 | |
| 2022-02-25 | TG Therapeutics, Inc. | $44 | Food and Beverage | In-kind items and services | UKONIQ Drug, Hematology | 2022 | |
| 2022-02-24 | TG Therapeutics, Inc. | $58 | Food and Beverage | In-kind items and services | UKONIQ Drug, Hematology | 2022 | |
| 2022-02-08 | E.R. Squibb & Sons, L.L.C. | $3,114 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-01-31 | TG Therapeutics, Inc. | $4,050 | Consulting Fee | Cash or cash equivalent | UKONIQ Drug, Hematology | 2022 | |
| 2022-01-28 | Genentech, Inc. | $3,300 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Biological, BioOncology | 2022 | |
| 2021-12-24 | ABBVIE INC. | $1,925 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2021 | |
| 2021-12-13 | Eli Lilly and Company | $125 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-12-13 | TG Therapeutics, Inc. | $105 | Food and Beverage | In-kind items and services | UKONIQ Drug, Hematology | 2021 | |
| 2021-12-12 | BeiGene USA, Inc. | $10 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2021 | |
| 2021-12-11 | AstraZeneca Pharmaceuticals LP | $83 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-12-11 | Genentech USA, Inc. | $53 | Food and Beverage | In-kind items and services | VENCLEXTA Biological, BioOncology | 2021 | |
| 2021-12-09 | ABBVIE INC. | $115 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2021 | |
| 2021-12-08 | AstraZeneca Pharmaceuticals LP | $3,767 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2021 | |
| 2021-11-05 | TG Therapeutics, Inc. | $243 | Food and Beverage | In-kind items and services | UKONIQ Drug, Hematology | 2021 | |
| 2021-11-04 | TG Therapeutics, Inc. | $122 | Food and Beverage | In-kind items and services | UKONIQ Drug, Hematology | 2021 | |
| 2021-10-25 | ABBVIE INC. | $150 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2021 | |
| 2021-10-21 | TG Therapeutics, Inc. | $48 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-10-21 | TG Therapeutics, Inc. | $14 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-10-18 | ABBVIE INC. | $2,200 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-10-13 | TG Therapeutics, Inc. | $22 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-10-07 | ABBVIE INC. | $1,100 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2021 | |
| 2021-10-07 | ABBVIE INC. | $1,100 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2021 | |
| 2021-10-04 | F. Hoffmann-La Roche AG | $3,468 | Research payment | In-kind items and services | VENCLEXTA Biological, BioOncology | REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA CLL RECEIVING FIRST-LINE 1L THE | 2021 |
| 2021-10-04 | Janssen Biotech, Inc. | $106 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, Oncology | 2021 | |
| 2021-09-30 | E.R. Squibb & Sons, L.L.C. | $1,691 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-09-22 | Pharmacyclics LLC, an AbbVie Company | $1,523 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-08-18 | Genentech, Inc. | $21 | Food and Beverage | In-kind items and services | VENCLEXTA Biological, BioOncology | 2021 | |
| 2021-08-11 | Genentech, Inc. | $1,650 | Consulting Fee | Cash or cash equivalent | Drug | 2021 | |
| 2021-08-10 | BeiGene, Ltd. | $6,500 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-08-08 | AstraZeneca Pharmaceuticals LP | $2,226 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2021 | |
| 2021-08-06 | BeiGene USA, Inc. | $1,625 | Consulting Fee | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2021 | |
| 2021-07-30 | Genentech, Inc. | $1,650 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Biological, BioOncology | 2021 | |
| 2021-07-14 | AstraZeneca Pharmaceuticals LP | $93 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2021 | |
| 2021-07-02 | PFIZER INC. | $1,260 | Honoraria | Cash or cash equivalent | RUXIENCE Biological, ONCOLOGY | 2021 | |
| 2021-06-22 | Pharmacyclics LLC, an AbbVie Company | $2,200 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | 2021 | |
| 2021-06-14 | Octapharma USA, Inc. | $2,500 | Honoraria | Cash or cash equivalent | PANZYGA Biological, IMMUNOLOGY | 2021 | |
| 2021-06-11 | ABBVIE INC. | $2,750 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2021 | |
| 2021-06-08 | Eli Lilly and Company | $2,875 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-05-20 | ABBVIE INC. | $112 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2021 | |
| 2021-05-20 | ABBVIE INC. | $58 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2021 | |
| 2021-04-29 | ABBVIE INC. | $825 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-04-15 | AstraZeneca Pharmaceuticals LP | $2,055 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2021 | |
| 2021-04-09 | ABBVIE INC. | $660 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2021 | |
| 2021-03-23 | BeiGene, Ltd. | $1,625 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-03-19 | Genentech, Inc. | $2,310 | Consulting Fee | Cash or cash equivalent | Drug | 2021 | |
| 2021-03-17 | AstraZeneca Pharmaceuticals LP | $2,740 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-02-01 | Merck Sharp & Dohme LLC | $2,500 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-01-26 | BeiGene, Ltd. | $1,950 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-01-24 | AstraZeneca Pharmaceuticals LP | $1,370 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-01-22 | Janssen Scientific Affairs, LLC | $1,515 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, Oncology | 2021 | |
| 2021-01-14 | AstraZeneca Pharmaceuticals LP | $537 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2021 | |
| 2021-01-10 | AstraZeneca Pharmaceuticals LP | $2,740 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2021 | |
| 2020-12-11 | Janssen Global Services, LLC | $1,240 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, Oncology | 2020 | |
| 2020-12-09 | Janssen Global Services, LLC | $2,800 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, Oncology | 2020 | |
| 2020-12-03 | ABBVIE INC. | $1,650 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2020 | |
| 2020-11-20 | Janssen Global Services, LLC | $1,860 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, Oncology | 2020 | |
| 2020-10-29 | Celgene Corporation | $3,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-09-25 | Janssen Global Services, LLC | $1,240 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, Oncology | 2020 | |
| 2020-07-23 | Janssen Biotech, Inc. | $1,010 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, Oncology | 2020 | |
| 2020-07-17 | BeiGene, Ltd. | $1,950 | Consulting Fee | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2020 | |
| 2020-07-15 | Janssen Global Services, LLC | $2,800 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, Oncology | 2020 | |
| 2020-07-07 | AstraZeneca Pharmaceuticals LP | $537 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2020 | |
| 2020-06-30 | F. Hoffmann-La Roche AG | $437 | Research payment | In-kind items and services | Venclexta Biological, BioOncology | A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSEDREFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | 2020 |
| 2020-06-11 | ABBVIE INC. | $1,375 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2020 | |
| 2020-06-01 | ABBVIE INC. | $1,100 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2020 | |
| 2020-05-29 | AstraZeneca Pharmaceuticals LP | $2,397 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2020 | |
| 2020-05-14 | AstraZeneca Pharmaceuticals LP | $537 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2020 | |
| 2020-03-31 | F. Hoffmann-La Roche AG | $364 | Research payment | In-kind items and services | Venclexta Biological, BioOncology | A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSEDREFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | 2020 |
| 2020-02-20 | AstraZeneca Pharmaceuticals LP | $1,370 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2020 | |
| 2020-02-05 | Verastem, Inc. | $1,450 | Consulting Fee | Cash or cash equivalent | Copiktra Drug, Hematology and Oncology | 2020 | |
| 2020-02-01 | Genentech, Inc. | $42 | Food and Beverage | In-kind items and services | Rituxan Biological, BioOncology/Immunology | 2020 | |
| 2020-01-31 | Genentech, Inc. | $5,940 | Consulting Fee | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | 2020 | |
| 2020-01-31 | Genentech, Inc. | $694 | Travel and Lodging | In-kind items and services | Rituxan Biological, BioOncology/Immunology | 2020 | |
| 2020-01-31 | Genentech, Inc. | $150 | Travel and Lodging | In-kind items and services | Rituxan Biological, BioOncology/Immunology | 2020 | |
| 2020-01-31 | Genentech, Inc. | $99 | Travel and Lodging | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | 2020 | |
| 2020-01-07 | AstraZeneca Pharmaceuticals LP | $1,074 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2020 | |
| 2020-01-06 | PFIZER INC. | $8,820 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2019-12-24 | Janssen Scientific Affairs, LLC | $3,100 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, Oncology | 2019 | |
| 2019-12-19 | Janssen Global Services, LLC | $2,480 | Consulting Fee | Cash or cash equivalent | IMBRUVICA Drug, Oncology | 2019 | |
| 2019-12-10 | Janssen Global Services, LLC | $67 | Travel and Lodging | In-kind items and services | IMBRUVICA Drug, Oncology | 2019 | |
| 2019-12-10 | Janssen Global Services, LLC | $49 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, Oncology | 2019 | |
| 2019-12-10 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | VENCLEXTA Biological, BioOncology | 2019 | |
| 2019-12-10 | Janssen Global Services, LLC | $12 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, Oncology | 2019 | |
| 2019-12-09 | Genentech, Inc. | $155 | Food and Beverage | In-kind items and services | VENCLEXTA Biological, BioOncology | 2019 | |
| 2019-12-07 | AstraZeneca Pharmaceuticals LP | $6 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-12-06 | Genentech USA, Inc. | $116 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-12-06 | ABBVIE INC. | $78 | Food and Beverage | In-kind items and services | Venclexta Drug, Virology | 2019 | |
| 2019-12-06 | AstraZeneca Pharmaceuticals LP | $43 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2019 | |
| 2019-12-06 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2019 | |
| 2019-12-05 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | Venclexta Drug, Virology | 2019 | |
| 2019-12-04 | Pharmacyclics LLC, an AbbVie Company | $90 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-26 | Celgene Corporation | $1,800 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-11-05 | Verastem, Inc. | $62 | Food and Beverage | In-kind items and services | Copiktra Drug, Hematology and Oncology | 2019 | |
| 2019-10-31 | Celgene Corporation | $2,866 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2019 | ||
| 2019-10-24 | Pharmacyclics LLC, an AbbVie Company | $1,750 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1142-CA | 2019 |
| 2019-10-21 | AstraZeneca Pharmaceuticals LP | $6,165 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2019 | |
| 2019-10-17 | Adaptive Biotechnologies Corporation | $1,800 | Consulting Fee | Cash or cash equivalent | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | 2019 | |
| 2019-10-15 | Pharmacyclics LLC, an AbbVie Company | $1,500 | Consulting Fee | Cash or cash equivalent | Imbruvica Drug, Oncology | 2019 | |
| 2019-10-10 | Verastem, Inc. | $3,262 | Consulting Fee | Cash or cash equivalent | Copiktra Drug, Hematology and Oncology | 2019 | |
| 2019-09-22 | Pharmacyclics LLC, an AbbVie Company | $67 | Food and Beverage | In-kind items and services | Imbruvica Drug, Oncology | 2019 | |
| 2019-09-22 | ABBVIE INC. | $39 | Food and Beverage | In-kind items and services | Venclexta Drug, Virology | 2019 | |
| 2019-09-21 | Genentech USA, Inc. | $22 | Food and Beverage | In-kind items and services | VENCLEXTA Biological, BioOncology | 2019 | |
| 2019-09-20 | Adaptive Biotechnologies Corporation | $32 | Food and Beverage | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | 2019 | |
| 2019-09-19 | Pharmacyclics LLC, an AbbVie Company | $40 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1142-CA | 2019 |
| 2019-09-19 | Verastem, Inc. | $11 | Food and Beverage | In-kind items and services | Copiktra Drug, Hematology and Oncology | 2019 | |
| 2019-09-06 | AstraZeneca Pharmaceuticals LP | $356 | Travel and Lodging | In-kind items and services | CALQUENCE Drug, Oncology | 2019 | |
| 2019-09-06 | AstraZeneca Pharmaceuticals LP | $236 | Travel and Lodging | In-kind items and services | CALQUENCE Drug, Oncology | 2019 | |
| 2019-09-06 | AstraZeneca Pharmaceuticals LP | $93 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2019 | |
| 2019-09-06 | AstraZeneca Pharmaceuticals LP | $78 | Travel and Lodging | In-kind items and services | CALQUENCE Drug, Oncology | 2019 | |
| 2019-09-06 | AstraZeneca Pharmaceuticals LP | $50 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2019 |
The latest 200 records of 248.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-16 | PFIZER INC. | Cayuga Medical Center At Ithaca | $6,300 | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BO | 2025 |
| 2025-05-02 | AstraZeneca Pharmaceuticals LP | MEMORIAL SLOAN-KETTERING CANCER | $142,819 | A time limited approach based on depth of response to front-line acalabrutinib monotherapy or in combination for chronic | 2025 |
| 2024-12-21 | PFIZER INC. | CAYUGA MEDICAL CENTER AT ITHACA | $19,200 | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BO | 2024 |
| 2024-10-09 | PFIZER INC. | Cayuga Medical Center | $2,257 | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BO | 2024 |
| 2024-10-08 | Eli Lilly and Company | MEMORIAL SLOAN-KETTERING | $1,638 | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS V | 2024 |
| 2024-08-08 | ABBVIE INC. | Hospital Of The Univ Of Penna | $9,763 | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | 2024 |
| 2024-07-12 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,942 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-07-12 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $1,644 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-07-12 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,942 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-07-12 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,407 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-06-12 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,556 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-06-12 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $1,644 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-06-12 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,437 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-06-12 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,437 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-05-13 | AstraZeneca Pharmaceuticals LP | Memorial Sloan Kettering Cancer Center | $553,251 | A time limited approach based on depth of response to front-line acalabrutinib monotherapy or in combination for chronic | 2024 |
| 2024-05-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,407 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-05-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $1,644 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-05-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,942 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-05-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,166 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-05-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,314 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-05-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,166 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-05-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $1,644 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-04-10 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $1,644 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-04-10 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,407 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-04-10 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,650 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-04-10 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,407 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-04-10 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $4,280 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-04-10 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,650 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-04-10 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,407 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,407 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,942 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,942 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,942 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,942 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $4,505 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,407 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $768 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,942 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,942 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $4,505 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,650 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-03-07 | AstraZeneca Pharmaceuticals LP | Memorial Sloan Kettering Cancer Center | $21,932 | A time limited approach based on depth of response to front-line acalabrutinib monotherapy or in combination for chronic | 2024 |
| 2024-02-07 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,942 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-02-07 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,942 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-02-07 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $365 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-02-07 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $882 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-02-07 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $4,953 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-02-07 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,942 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-02-07 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,526 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2024 |
| 2024-01-11 | AstraZeneca Pharmaceuticals LP | MEMORIAL SLOAN-KETTERING CANCER | $254,390 | A time limited approach based on depth of response to front-line acalabrutinib monotherapy or in combination for chronic | 2024 |
| 2023-11-13 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $25,710 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-10-11 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $18,680 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-10-03 | AstraZeneca Pharmaceuticals LP | Memorial Sloan Kettering Cancer Center | $39,301 | A time limited approach based on depth of response to front-line acalabrutinib monotherapy or in combination for chronic | 2023 |
| 2023-08-21 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $10,004 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-08-21 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $810 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-08-21 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $20,936 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-08-09 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $6,357 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-08-01 | AstraZeneca UK Limited | Memorial Sloan Kettering Cancer Center | $140,199 | MAJIC A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoc | 2023 |
| 2023-07-01 | TG Therapeutics, Inc. | Pontchartrain Cancer Center | $2,546 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL | 2023 |
| 2023-07-01 | TG Therapeutics, Inc. | Pontchartrain Cancer Center | $6,629 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL | 2023 |
| 2023-07-01 | TG Therapeutics, Inc. | Pontchartrain Cancer Center | $3,162 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL | 2023 |
| 2023-07-01 | TG Therapeutics, Inc. | Pontchartrain Cancer Center | $3,162 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL | 2023 |
| 2023-07-01 | TG Therapeutics, Inc. | Pontchartrain Cancer Center | $6,629 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL | 2023 |
| 2023-07-01 | TG Therapeutics, Inc. | Pontchartrain Cancer Center | $2,546 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL | 2023 |
| 2023-06-26 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,121 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-06-26 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,278 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-06-26 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,185 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-06-26 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $3,872 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-06-07 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $40,805 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-06-03 | AstraZeneca Pharmaceuticals LP | MEMORIAL SLOAN KETTERING CANCER CENTER OF COMMACK | $29,011 | A time limited approach based on depth of response to front-line acalabrutinib monotherapy or in combination for chronic | 2023 |
| 2023-05-10 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $30,178 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-04-17 | BeiGene, Ltd. | MEMORIAL SLOANKETTERING CANCER CENTER | $49,809 | A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB- | 2023 |
| 2023-04-15 | AstraZeneca Pharmaceuticals LP | MEMORIAL SLOAN-KETTERING CANCER | $59,892 | A time limited approach based on depth of response to front-line acalabrutinib monotherapy or in combination for chronic | 2023 |
| 2023-04-07 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $5,832 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-03-15 | BeiGene, Ltd. | Memorial Sloan Kettering Cancer Center | $17,864 | A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB- | 2023 |
| 2023-03-09 | AstraZeneca Pharmaceuticals LP | Memorial Sloan Kettering Cancer Center | $5,550,422 | A time limited approach based on depth of response to front-line acalabrutinib monotherapy or in combination for chronic | 2023 |
| 2023-03-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $25,757 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-02-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $55,042 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-02-08 | Eli Lilly and Company | MEMORIAL SLOAN-KETTERING | $1,134 | A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VE | 2023 |
| 2023-02-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $14,984 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-02-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $2,430 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-02-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $23,190 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-02-08 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $15,006 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-02-03 | BeiGene, Ltd. | MEMORIAL SLOANKETTERING CANCER CENTER | $1,705 | A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB- | 2023 |
| 2023-02-03 | BeiGene, Ltd. | Memorial Sloan Kettering Cancer Center | $5,531 | A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB- | 2023 |
| 2023-02-03 | BeiGene, Ltd. | Memorial Sloan Kettering Cancer Center | $15,964 | A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB- | 2023 |
| 2023-02-03 | BeiGene, Ltd. | Memorial Sloan Kettering Cancer Center | $2,841 | A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB- | 2023 |
| 2023-02-01 | TG Therapeutics, Inc. | Pontchartrain Cancer Center | $187 | Phase I study of ublituximab and umbralisib in combination with targeted immunotherapy in patients with relapsed-refract | 2023 |
| 2023-02-01 | TG Therapeutics, Inc. | Pontchartrain Cancer Center | $187 | Phase I study of ublituximab and umbralisib in combination with targeted immunotherapy in patients with relapsed-refract | 2023 |
| 2023-02-01 | TG Therapeutics, Inc. | Pontchartrain Cancer Center | $13,665 | Phase I study of ublituximab and umbralisib in combination with targeted immunotherapy in patients with relapsed-refract | 2023 |
| 2023-02-01 | TG Therapeutics, Inc. | Pontchartrain Cancer Center | $13,665 | Phase I study of ublituximab and umbralisib in combination with targeted immunotherapy in patients with relapsed-refract | 2023 |
| 2023-01-27 | Genentech, Inc. | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | $366,683 | Venetoclax based combination therapy in CLL patients in the front line setting | 2023 |
| 2023-01-26 | Eli Lilly and Company | MEMORIAL SLOAN-KETTERING | $376,032 | A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LY | 2023 |
| 2023-01-26 | Eli Lilly and Company | MEMORIAL SLOAN-KETTERING | $13 | A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LY | 2023 |
| 2023-01-11 | Genmab A/S | Memorial Sloan Kettering Cancer Center | $13,908 | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-01-06 | Eli Lilly and Company | MEMORIAL SLOAN-KETTERING | $253,268 | A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VE | 2023 |
| 2022-12-27 | Adaptive Biotechnologies Corporation | Memorial Hospital For Cancer And All | $1,650 | Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposu | 2022 |
| 2022-12-26 | AstraZeneca UK Limited | Memorial Sloan Kettering Cancer Center | $16,656 | MAJIC A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoc | 2022 |
| 2022-12-26 | Adaptive Biotechnologies Corporation | Memorial Hospital For Cancer And All | $550 | Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposu | 2022 |
| 2022-12-24 | Adaptive Biotechnologies Corporation | Memorial Hospital For Cancer And All | $550 | Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposu | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Ithaca, NY, county Tompkins County, NY, state New York; placed by its city name.
| Measure | Place (city or town) Ithaca, NY | County Tompkins County, NY | State New York |
|---|---|---|---|
| Population B01003 | 32,814 | 104,537 | 19,852,366 |
| Population, 2020 census P1 | 32,108 | 105,740 | 20,201,249 |
| Median age B01002 | 23.3 | 32.3 | 39.8 |
| Under 18 B01001 | 7.1% | 14.1% | 20.5% |
| 65 and over B01001 | 10.1% | 16.3% | 17.9% |
| Households B11001 | 14,167 | 43,263 | 7,722,646 |
| Foreign born B05002 | 20.0% | 12.9% | 22.8% |
| Median household income B19013 | $48,784 | $74,024 | $85,974 |
| Median family income B19113 | $120,341 | $114,291 | $106,873 |
| Per capita income B19301 | $31,599 | $41,808 | $50,712 |
| Poverty rate B17001 | 30.4% | 16.4% | 14.0% |
| Unemployment rate B23025 | 7.3% | 5.5% | 6.4% |
| Civilian labor force B23025 | 16,145 | 53,455 | 10,171,766 |
| Mean commute (minutes) B08013 | 18.7 | 20.1 | 32.6 |
| Bachelor's degree or higher B15003 | 67.7% | 58.8% | 40.2% |
| Housing units B25001 | 16,183 | 47,804 | 8,585,241 |
| Owner-occupied B25003 | 29.6% | 54.1% | 54.3% |
| Renters B25003 | 70.4% | 45.9% | 45.7% |
| Median home value B25077 | $342,700 | $290,900 | $423,800 |
| Median gross rent B25064 | $1,447 | $1,411 | $1,621 |
| White, not Hispanic B03002 | 62.6% | 73.7% | 52.8% |
| Black B03002 | 5.4% | 3.6% | 13.4% |
| Hispanic or Latino B03002 | 8.8% | 6.6% | 19.8% |
| Asian B03002 | 16.5% | 10.1% | 9.0% |
| American Indian and Alaska Native B03002 | 0.3% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Ithaca, NY.
Comments